NextFin News - Sun Pharmaceutical Industries Ltd. is moving to secure a complex multi-billion dollar financing package to bankroll its $11.75 billion acquisition of Organon & Co., marking the largest outbound deal in the history of the Indian pharmaceutical sector. Global lenders, including Mitsubishi UFJ Financial Group Inc., JPMorgan Chase & Co., and Citigroup Inc., have committed to a bridge loan facility that will serve as the immediate foundation for the all-cash transaction, according to people familiar with the matter. The deal, which values the New York-listed Organon at $14 per share, represents a significant pivot for Sun Pharma as it seeks to dominate the global women’s health and biosimilars markets.
The financing structure currently under review involves a sophisticated mix of internal accruals and external debt. Sun Pharma plans to deploy between $2 billion and $2.5 billion from its existing cash reserves to cover the equity portion of the deal. The remaining $9.25 billion to $9.75 billion will be sourced through a combination of offshore bank loans and potential capital market instruments. Sources indicate that the company is exploring the issuance of Eurobonds and the use of bond swaps to optimize its interest costs, reflecting a strategy to diversify its creditor base beyond traditional bank lending.
Prabhudas Lilladher, a brokerage that has historically maintained a constructive but data-driven outlook on Indian large-cap pharma, suggests that the deal will likely push Sun Pharma’s net debt-to-EBITDA ratio to approximately 2.3x. While this represents a sharp increase from the company’s traditionally conservative balance sheet, the brokerage notes that the robust cash flow generation from Organon’s portfolio—which includes over 70 products across 140 countries—should support rapid deleveraging. However, this assessment is based on the assumption of seamless integration and the maintenance of Organon’s current margins, a feat that has challenged other Indian firms pursuing large-scale U.S. acquisitions in the past.
The acquisition is not without its skeptics. Some market participants argue that the 60% premium paid over Organon’s January closing price is steep, especially given the competitive pressures in the biosimilars space. This cautious perspective, held by a minority of sell-side analysts, suggests that the "all-cash" nature of the deal places the entirety of the execution risk on Sun Pharma’s shareholders. Unlike stock-swap deals, this structure offers no downside protection if the anticipated synergies in women’s health—a category Sun Pharma believes is insulated from U.S. generic pricing erosion—fail to materialize at scale.
Strategically, the merger is designed to propel Sun Pharma into the top 25 global pharmaceutical companies, with a projected combined annual revenue of $12.4 billion. By absorbing Organon, a 2021 spin-off from Merck & Co., Sun Pharma gains an established commercial infrastructure in high-growth markets, including China. The success of the venture will ultimately hinge on whether Sun Pharma can manage the transition from a generics-heavy model to one led by Organon’s specialized innovative therapies without overextending its financial capacity during a period of volatile global interest rates.
Explore more exclusive insights at nextfin.ai.
